CNR1 and Parkinson disease: Consequently, it was shown that sustained treatment with quinpirole influenced the expression of D2LR, which in turn might affect the dimerization status inside the cell as: D2LR − CB1 > D2LR − D2LR > A2A − D2LR. In a similar way, studies also indicated that a CB1 antagonist (1-(7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo (1,5-a)-(1,3,5)triazin-4-yl)-3-ethylaminoazetidine-3-carboxylic acid amide benzenesulfonate) could have a potential therapeutic role in Parkinsonism by enhancing the activity of L-DOPA [82].